Table 2.
3D-Γ analysis for investigated patient cases evaluating FRoG with RS-MC as reference, presenting mean (µ) and standard deviation (σ) in passing rate within the cohort
| 3D-Γ passing rates – FRoG vs. RS-MC | ||||||||
|---|---|---|---|---|---|---|---|---|
| Test | Type | Dose threshold (DT) | 2%/2mm | 3%/1.5mm | 5%/1mm | |||
| μ | ±σ | μ | ±σ | μ | ±σ | |||
| 3D-Γ | Local | DT10 | 97.3 | 1.7 | 96.1 | 2.2 | 94.7 | 2.4 |
| DT50 | 97.8 | 1.9 | 96.8 | 2.5 | 96.0 | 2.4 | ||
| DT90 | 96.7 | 3.4 | 97.1 | 3.0 | 98.6 | 1.6 | ||
| Global | DT10 | 98.3 | 1.2 | 97.5 | 1.6 | 97.5 | 1.5 | |
| DT50 | 98.0 | 1.9 | 97.2 | 2.3 | 97.1 | 2.0 | ||
| DT90 | 96.7 | 3.4 | 97.2 | 3.1 | 98.6 | 1.6 | ||
| Percent derivation (%Δ) in DVH metric – FRoG vs. RS-MC | ||||||||
|---|---|---|---|---|---|---|---|---|
| Test | Structure | %ΔD98 | %ΔD50 | %ΔD2 | ||||
| μ | ±σ | μ | ±σ | μ | ±σ | |||
| DVH | CTV | 0.49 | 0.29 | 0.26 | 0.22 | 0.43 | 0.38 | |
| Brainstem | – | – | 0.37 | 0.24 | 1.63 | 2.06 | ||
| Chiasma | – | – | 0.70 | 0.90 | 1.00 | 1.32 | ||
| Optic nerve (R) | – | – | 0.38 | 0.36 | 0.52 | 0.33 | ||
| Optic nerve (L) | – | – | 2.68 | 3.23 | 0.54 | 0.89 | ||
Percent mean DRBE deviation in dose metrics (µ ± σ) applying fixed RBE = 1.1 between FRoG and RS-MC within the patient cohort